Nang Kuang Pharmaceutical Co., Ltd. (1752.TW)
TWD 35.65
(3.78%)
TWD 35.65
(3.78%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 12.56 Million TWD | -50.88% |
| 2022 | 25.58 Million TWD | -34.48% |
| 2021 | 39.05 Million TWD | -22.56% |
| 2020 | 50.42 Million TWD | -4.86% |
| 2019 | 53 Million TWD | -49.03% |
| 2018 | 104 Million TWD | -33.33% |
| 2017 | 156 Million TWD | -25.0% |
| 2016 | 208 Million TWD | -41.57% |
| 2015 | 356 Million TWD | -54.93% |
| 2014 | 789.82 Million TWD | -7.15% |
| 2013 | 850.69 Million TWD | -1.08% |
| 2012 | 860 Million TWD | 29.17% |
| 2011 | 665.77 Million TWD | -7.3% |
| 2010 | 718.19 Million TWD | 83.54% |
| 2009 | 391.3 Million TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 12.55 Million TWD | 0.0% |
| 2024 Q2 | 106.25 Million TWD | -5.56% |
| 2023 Q4 | 12.56 Million TWD | -33.25% |
| 2023 Q1 | 25.3 Million TWD | -1.08% |
| 2023 FY | 12.56 Million TWD | -50.88% |
| 2023 Q2 | 18.84 Million TWD | -25.56% |
| 2023 Q3 | 18.82 Million TWD | -0.06% |
| 2022 Q3 | 32.07 Million TWD | -0.74% |
| 2022 FY | 25.58 Million TWD | -34.48% |
| 2022 Q4 | 25.58 Million TWD | -20.23% |
| 2022 Q2 | 32.31 Million TWD | -16.76% |
| 2022 Q1 | 38.82 Million TWD | -0.59% |
| 2021 Q2 | 44 Million TWD | -12.73% |
| 2021 Q3 | 45.55 Million TWD | 3.53% |
| 2021 FY | 39.05 Million TWD | -22.56% |
| 2021 Q4 | 39.05 Million TWD | -14.28% |
| 2021 Q1 | 50.42 Million TWD | 0.0% |
| 2020 Q4 | 50.42 Million TWD | 89.6% |
| 2020 Q2 | 26.59 Million TWD | -49.71% |
| 2020 FY | 50.42 Million TWD | -4.86% |
| 2020 Q3 | 26.59 Million TWD | 0.0% |
| 2020 Q1 | 52.88 Million TWD | -0.22% |
| 2019 Q1 | 104 Million TWD | 0.0% |
| 2019 Q4 | 53 Million TWD | -33.17% |
| 2019 FY | 53 Million TWD | -49.03% |
| 2019 Q3 | 79.31 Million TWD | -0.15% |
| 2019 Q2 | 79.42 Million TWD | -23.63% |
| 2018 Q2 | 130 Million TWD | -16.67% |
| 2018 Q3 | 130 Million TWD | 0.0% |
| 2018 FY | 104 Million TWD | -33.33% |
| 2018 Q1 | 156 Million TWD | 0.0% |
| 2018 Q4 | 104 Million TWD | -20.0% |
| 2017 Q3 | 182 Million TWD | 0.0% |
| 2017 Q4 | 156 Million TWD | -14.29% |
| 2017 FY | 156 Million TWD | -25.0% |
| 2017 Q1 | 208 Million TWD | 0.0% |
| 2017 Q2 | 182 Million TWD | -12.5% |
| 2016 Q4 | 208 Million TWD | 0.0% |
| 2016 FY | 208 Million TWD | -41.57% |
| 2016 Q3 | - TWD | 0.0% |
| 2016 Q2 | - TWD | -100.0% |
| 2016 Q1 | 356 Million TWD | 0.0% |
| 2015 Q3 | 573.82 Million TWD | -23.23% |
| 2015 Q4 | 356 Million TWD | -37.96% |
| 2015 FY | 356 Million TWD | -54.93% |
| 2015 Q1 | 763.23 Million TWD | -3.37% |
| 2015 Q2 | 747.48 Million TWD | -2.06% |
| 2014 Q2 | 805.26 Million TWD | -1.91% |
| 2014 Q1 | 820.97 Million TWD | -3.49% |
| 2014 Q4 | 789.82 Million TWD | -1.95% |
| 2014 Q3 | 805.54 Million TWD | 0.04% |
| 2014 FY | 789.82 Million TWD | -7.15% |
| 2013 Q4 | 850.69 Million TWD | 27.16% |
| 2013 Q1 | 556 Million TWD | -35.35% |
| 2013 Q2 | 701 Million TWD | 26.08% |
| 2013 Q3 | 669 Million TWD | -4.56% |
| 2013 FY | 850.69 Million TWD | -1.08% |
| 2012 FY | 860 Million TWD | 29.17% |
| 2012 Q1 | 658.26 Million TWD | -1.13% |
| 2012 Q4 | 860 Million TWD | 4.56% |
| 2012 Q3 | 822.5 Million TWD | -2.08% |
| 2012 Q2 | 840 Million TWD | 27.61% |
| 2011 Q3 | 689.66 Million TWD | 5.3% |
| 2011 FY | 665.77 Million TWD | -7.3% |
| 2011 Q1 | 717.91 Million TWD | -0.04% |
| 2011 Q2 | 654.94 Million TWD | -8.77% |
| 2011 Q4 | 665.77 Million TWD | -3.46% |
| 2010 Q4 | 718.19 Million TWD | 0.0% |
| 2010 FY | 718.19 Million TWD | 83.54% |
| 2009 FY | 391.3 Million TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Maxigen Biotech Inc. | - TWD | -Infinity% |
| SciVision Biotech Inc. | 346.69 Million TWD | 96.375% |
| Bionime Corporation | 1.69 Billion TWD | 99.26% |
| Pegavision Corporation | 365.09 Million TWD | 96.558% |
| Visco Vision Inc. | 848.86 Million TWD | 98.52% |